Evaluating SGLT2 inhibitors for type 2 diabetes: Pharmacokinetic and toxicological considerations

Expert Opinion on Drug Metabolism and Toxicology

Volumn 10, Issue 5, 2014, Pages 647-663

  Scheen, André J ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Canagliflozin; Dapagliflozin; Empagliflozin; Glucose lowering therapy; Pharmacokinetics; Safety; Type 2 diabetes mellitus

Indexed keywords

ANTIDIABETIC AGENT; CANAGLIFLOZIN; CYCLOSPORIN; DAPAGLIFLOZIN; DIGOXIN; DRUG METABOLITE; EMPAGLIFLOZIN; ETHINYLESTRADIOL; GLIBENCLAMIDE; GLIMEPIRIDE; HYDROCHLOROTHIAZIDE; LEVONORGESTREL; LINAGLIPTIN; MEFENAMIC ACID; METFORMIN; PIOGLITAZONE; PROBENECID; RIFAMPICIN; SIMVASTATIN; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; TORASEMIDE; UNCLASSIFIED DRUG; VALSARTAN; VERAPAMIL; VOGLIBOSE; WARFARIN; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; AGENTS AFFECTING WATER, MOLECULE OR ION TRANSPORT; BENZHYDRYL DERIVATIVE; GLUCOSIDE; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2; THIOPHENE DERIVATIVE;

AREA UNDER THE CURVE; BACTERIURIA; BALANITIS; BLADDER CANCER; BREAST CANCER; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); DIABETIC PATIENT; DISEASE SEVERITY; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG SAFETY; FRACTURE; FUNGAL GENITAL INFECTION; GLUCOSURIA; HUMAN; HYPOGLYCEMIA; INCIDENCE; KIDNEY CLEARANCE; KIDNEY DYSFUNCTION; MILD HEPATIC IMPAIRMENT; MODERATE HEPATIC IMPAIRMENT; NEPHROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORTHOSTATIC HYPOTENSION; REVIEW; RISK REDUCTION; SEVERE HEPATIC IMPAIRMENT; TACHYCARDIA; URINARY TRACT INFECTION; VULVOVAGINITIS; ANTAGONISTS AND INHIBITORS; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHY; DRUG INTERACTION; KIDNEY FAILURE; LIVER FAILURE; METABOLISM;

BENZHYDRYL COMPOUNDS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DRUG INTERACTIONS; GLUCOSIDES; HEPATIC INSUFFICIENCY; HUMANS; HYPOGLYCEMIC AGENTS; MEMBRANE TRANSPORT MODULATORS; RENAL INSUFFICIENCY; SODIUM-GLUCOSE TRANSPORTER 2; THIOPHENES;

EID: 84898434447     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2014.873788     Document Type: Review

References (79)

1. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012;55:1577-96
2. Freeman JS. Review of insulin-dependent and insulin-independent agents for treating patients with type 2 diabetes mellitus and potential role for sodium-glucose co-transporter 2 inhibitors. Postgrad Med 2013;125:214-26
3. Abdul-Ghani MA, Norton L, Defronzo RA. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev 2011;32:515-31
4. Plosker GL. Dapagliflozin: a review of its use in type 2 diabetes mellitus. Drugs 2012;72:2289-312
5. Elkinson S, Scott LJ. Canagliflozin: first global approval. Drugs 2013;73:979-88
6. Lamos EM, Younk LM, Davis SN. Canagliflozin, an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol 2013;9:763-75
7. Scheen AJ. Pharmacokinetic and pharmacodynamic profile of empagliflozin. a sodium glucose co-transporter 2 inhibitor. Clin Pharmacokinet 2013; In press
8. Kurosaki E, Ogasawara H. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data. Pharmacol Ther 2013;139:51-9
9. Washburn WN, Poucher SM. Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus. Expert Opin Investig Drugs 2013;22:463-86
10. Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 2013;159:262-74
11. Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med 2010;27:136-42
12. Bailey CJ. Renal glucose reabsorption inhibitors to treat diabetes. Trends Pharmacol Sci 2011;32:63-71
13. Barnett AH. Impact of sodium glucose cotransporter 2 inhibitors on weight in patients with type 2 diabetes mellitus. Postgrad Med 2013;125:92-100
14. Neumiller JJ, White JR Jr, Campbell RK. Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus. Drugs 2010;70:377-85
15. Obermeier M, Yao M, Khanna A, et al. In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans. Drug Metab Dispos 2010;38:405-14
16. Kasichayanula S, Liu X, Lacreta F, et al. Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet 2013;published on line 2013/10/10; doi: 10.1007/s40262-013-0104-3
17. Gould JC, Kasichayanula S, Shepperly DC, et al. Use of low-dose clinical pharmacodynamic and pharmacokinetic data to establish an occupational exposure limit for dapagliflozin, a potent inhibitor of the renal sodium glucose co-transporter 2. Regul Toxicol Pharmacol 2013;67:89-97
18. Yang L, Li H, Bui A, et al. Pharmacokinetic and pharmacodynamic properties of single-and multiple-dose of dapagliflozin, a selective inhibitor of SGLT2, in healthy Chinese subjects. Clin Ther 2013;35:1211-22, e2
19. Kasichayanula S, Liu X, Zhang W, et al. Effect of a high-fat meal on the pharmacokinetics of dapagliflozin, a selective SGLT2 inhibitor, in healthy subjects. Diabetes Obes Metab 2011;13:770-3
20. Kasichayanula S, Chang M, Hasegawa M, et al. Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus. Diabetes Obes Metab 2011;13:357-65
21. Kasichayanula S, Liu X, Zhang W, et al. Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an open-label, parallel-group, single-dose study. Clin Ther 2011;33:1798-808
22. Komoroski B, Vachharajani N, Boulton D, et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther 2009;85:520-6
23. Janssen Pharmaceuticals, Inc. InvokanaTM (canagliflozin) tablets, for oral use: US prescribing information 2013 (issued March 2013). Available from: http/wwwjanssenmdcom/pdf/invokana/PI-INVOKANApdf [Accessed 11 October 2013]
24. Sha S, Devineni D, Ghosh A, et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab 2011;13:669-72
25. Food and Drug Administration. Center for Drug Evaluation and Research report. Canagliflozin (Invokana). Available from: http://wwwaccessdatafdagov/ drugsatfda-docs/nda/2013/204042Orig1s000ClinPharmRpdf [Accessed 21 October 2013]
26. Seman L, Macha S, Nehmiz G, et al. Empagliflozin (BI 10773), a potent and selective SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Drug Dev 2013;2:152-61
27. Sarashina A, Koiwai K, Seman LJ, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in healthy Japanese subjects. Drug Metab Pharmacokinet 2013;28:213-19
28. Macha S, Jungnik A, Hohl K, et al. Effect of food on the pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, and assessment of dose proportionality in healthy volunteers. Int J Clin Pharmacol Ther 2013;51:873-9
29. Kasichayanula S, Liu X, Pe Benito M, et al. The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus. Br J Clin Pharmacol 2013;76:432-44
30. Devineni D, Morrow L, Hompesch M, et al. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab 2012;14:539-45
31. Devineni D, Curtin CR, Polidori D, et al. Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus. J Clin Pharmacol 2013;53:601-10
32. Heise T, Seman L, Macha S, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitus. Diabetes Ther 2013;published on line 2013/07/11; doi: 10.1007/s13300-013-0030-2
33. Heise T, Seewaldt-Becker E, Macha S, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes Obes Metab 2013;15:613-21
34. Riggs MM, Staab A, Seman L, et al. Population pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with type 2 diabetes. J Clin Pharmacol 2013;53:1028-38
35. Scheen AJ. Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease. Expert Opin Drug Metab Toxicol 2013;9:529-50
36. Kohan DE, Fioretto P, Tang W, et al. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 2013;published on line 2013/09/27; doi: 10.1038/ki.2013.356
37. van der Walt JS, Hong Y, Zhang L, et al. A nonlinear mixed effects pharmacokinetic model for dapagliflozin and dapagliflozin 3-O-glucuronide in renal or hepatic impairment. CPT Pharmacometrics Syst Pharmacol 2013;2:e42
38. Devineni D, Marbury T, Curtin C, et al. Effects of renal function on canagliflozin (CANA) pharmacokinetics (PK) and pharmacodynamics (PD) in non-diabetic subjects [abstract# PUB295]. JASN Abstract Supplement of the American Society of Nephrology (ASN) Kidney Week; 30 October-4 November 2012; San Diego, CA
39. Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 2013;15:463-73
40. Macha S, Mattheus M, Halabi A, et al. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment. Diabetes Obes Metab 2013;published on line 2013/07/19; doi: 10.1111/dom.12182
41. Macha S, Rose P, Mattheus M, et al. Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairment. Diabetes Obes Metab 2013;published on line 2013/07/19; doi: 10.1111/dom.12183
42. Scheen AJ. Drug interactions of clinical importance with antihyperglycaemic agents-an update. Drug Saf 2005;28:601-31
43. Scheen AJ. Drug-drug interactions with SGLT-2 inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes. Clin Pharmacokinet 2013; in press
44. Kasichayanula S, Liu X, Shyu WC, et al. Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects. Diabetes Obes Metab 2011;13:47-54
45. Imamura A, Kusunoki M, Ueda S, et al. Impact of voglibose on the pharmacokinetics of dapagliflozin in Japanese patients with type 2 diabetes. Diabetes Ther 2013;4:41-9
46. Kasichayanula S, Chang M, Liu X, et al. Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin. Adv Ther 2012;29:163-77
47. Kasichayanula S, Liu X, Griffen SC, et al. Effects of rifampin and mefenamic acid on the pharmacokinetics and pharmacodynamics of dapagliflozin. Diabetes Obes Metab 2013;15:280-3
48. Devineni D, Sarich TC, Wexler D, et al. Effects of canagliflozin on the pharmacokinetics (PK) and pharmacodynamics (PD) of metformin and glyburide [abstract # 2268-PO]. Abstract presented at American Diabetes Association (ADA) 71st Scientific Sessions; 24-28 June 2011; San Diego, CA
49. Macha S, Sennewald R, Rose P, et al. Lack of clinically relevant drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and verapamil, ramipril, or digoxin in healthy volunteers. Clin Ther 2013;35:226-35
50. Skee D, Shalayda K, Vandebosch A, et al. The effects of multiple doses of canagliflozin on the pharmacokinetics and safety of single doses of an oral contraceptive containing ethinyl estradiol and levonorgestrel. Poster presented at the 111th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT); 17-20 March 2010; Atlanta, Georgia
51. Macha S, Dieterich S, Mattheus M, et al. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT2) inhibitor, and metformin following co-administration in healthy volunteers. Int J Clin Pharmacol Ther 2013;51:132-40
52. Macha S, Mattheus M, Pinnetti S, et al. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, and glimepiride following co-administration in healthy volunteers: a randomised, open-label, crossover study. Diabetes Res Clin Metab 2012;1:1-7
53. Brand T, Macha S, Mattheus M, et al. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy volunteers. Adv Ther 2012;29:889-99
54. Friedrich C, Metzmann K, Rose P, et al. A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers. Clin Ther 2013;35:A33-42
55. Macha S, Rose P, Mattheus M, et al. Lack of drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and warfarin in healthy volunteers. Diabetes Obes Metab 2013;15:316-23
56. Macha S, Lang B, Pinnetti S, et al. Lack of pharmacokinetic interaction between the sodium glucose cotransporter-2 (SGLT-2) inhibitor empagliflozin and simvastatin in healthy volunteers [abstract PCS-33-7]. J Diabetes Invest 2012;3:228
57. Macha S, Sennewald R, Rose P, et al. Lack of clinically relevant drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and verapamil, ramipril, or digoxin in healthy volunteers. Clin Ther 2013;35:226-35
58. Giessmann T, Heise T, Macha S, et al. Lack of interaction between the sodium glucose cotransporter-2 inhibitor empagliflozin and hydrochlorothiazide or torasemide in patients with T2DM [abstract 2440-PO]. Diabetes 2012;61:A614
59. Macha S, Mattheus M, Pinnetti S, et al. Effect of empagliflozin on the steady-state pharmacokinetics of ethinylestradiol and levonorgestrel in healthy female volunteers. Clin Drug Investig 2013;33:351-7
60. Riser Taylor S, Harris KB. The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus. Pharmacotherapy 2013;33:984-99
61. Johnsson KM, Ptaszynska A, Schmitz B, et al. Urinary tract infections in patients with diabetes treated with dapagliflozin. J Diabetes Complications 2013;27:473-8
62. Nicolle LE, Capuano G, Ways K, et al. Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study. Curr Med Res Opin 2012;28:1167-71
63. Johnsson KM, Ptaszynska A, Schmitz B, et al. Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J Diabetes Complications 2013;27:479-84
64. Nyirjesy P, Zhao Y, Ways K, et al. Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. Curr Med Res Opin 2012;28:1173-8
65. Woerle HJ, Ferrannini E, Berk A, et al. Safety and efficacy of empagliflozin as monotherapy or add-on to metformin in a 78-week open-label extension study in patients with type 2 diabetes. Diabetes 2012;61:abstract 49-LB
66. Lambers Heerspink HJ, de Zeeuw D, Wie L, et al. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 2013;15:853-62
67. Gilbert RE. Sodium-glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering? Kid Int 2013;published on line 2013/11/22; doi 10.1038/ki.2013.451
68. Barnett AH. Impact of sodium glucose cotransporter 2 inhibitors on weight in patients with type 2 diabetes mellitus. Postgrad Med 2013;125:92-100
69. Scheen AJ, Van Gaal LF. Combatting the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes. Lancet Diabetes Endocrinol 2013; In press
70. Ljunggren O, Bolinder J, Johansson L, et al. Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. Diabetes Obes Metab 2012;14:990-9
71. Guthrie RM. Sodium-glucose co-transporter 2 inhibitors and the potential for cardiovascular risk reduction in patients with type 2 diabetes mellitus. Postgrad Med 2013;125:21-32
72. Basile JN. The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM). J Diabetes Complications 2013;27:280-6
73. Goldfine AB. Assessing the cardiovascular safety of diabetes therapies. N Engl J Med 2008;359:1092-5
74. Neal B, Perkovic V, de Zeeuw D, et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)-a randomized placebo-controlled trial. Am Heart J 2013;166:217-23, e11
75. Inzucchi SE, Zinman B, Lachin JM, et al. Design of the empagliflozin cardiovascular outcome event trial in type 2 diabetes mellitus [abstract 944]. Diabetologia 2013;56(Suppl 1):S378
76. Ridderstrale M, Svaerd R, Zeller C, et al. Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control. Cardiovasc Diabetol 2013;12:129
77. Foote C, Perkovic V, Neal B. Effects of SGLT2 inhibitors on cardiovascular outcomes. Diab Vasc Dis Res 2012;9:117-23
78. Smith U, Gale EA. Does diabetes therapy influence the risk of cancer? Diabetologia 2009;52:1699-708
79. Burki TK. FDA rejects novel diabetes drug over safety fears. Lancet 2012;379:507